NCT07590570

Brief Summary

This is a multicentre study to investigate the association of fingernail lunula status with the efficacy and safety of neoadjuvant therapy in breast cancer patients.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
188

participants targeted

Target at P50-P75 for all trials

Timeline
80mo left

Started May 2026

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress1%
May 2026Jan 2033

Study Start

First participant enrolled

May 1, 2026

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

May 10, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 15, 2026

Completed
4.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2031

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2033

Last Updated

May 15, 2026

Status Verified

May 1, 2026

Enrollment Period

4.7 years

First QC Date

May 10, 2026

Last Update Submit

May 10, 2026

Conditions

Breast Cancer Invasive

Outcome Measures

Primary Outcomes (1)

  • Pathological Complete Response (pCR) Rate

    ypT0 ypN0

    at surgery

Secondary Outcomes (1)

  • Disease-free Survival

    From surgery until time of event up to 8 years

Study Arms (2)

retrospective

no requirements for therapy

Drug: neoadjuvant therapy

prospective

no requirements for therapy

Drug: neoadjuvant therapy

Interventions

neoadjuvant therapyDRUG

patients receiving neoadjuvant therapy

prospectiveretrospective

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Breast cancer patients who have received or plan to receive neoadjuvant therapy.

You may qualify if:

  • Aged 18 years or older
  • Pathologically confirmed invasive primary breast cancer
  • Patients who have received or are scheduled to receive neoadjuvant therapy

You may not qualify if:

  • De novo stage IV breast cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Renji Hospital, School of Medicine, Shanghai Jiaotong University

Shanghai, 200127, China

Location

MeSH Terms

Interventions

Neoadjuvant Therapy

Intervention Hierarchy (Ancestors)

Combined Modality TherapyTherapeutics

Study Officials

  • Wenjin Yin

    Renji Hospital, School of Medicine, Shanghai Jiaotong University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Deputy Chief of Breast Surgery Department

Study Record Dates

First Submitted

May 10, 2026

First Posted

May 15, 2026

Study Start

May 1, 2026

Primary Completion (Estimated)

January 1, 2031

Study Completion (Estimated)

January 1, 2033

Last Updated

May 15, 2026

Record last verified: 2026-05

Locations

CN(1)